New York Times Prescription For Health Care Costs: Stop Innovating

  • by: |
  • 03/20/2013
In what either be described as a glass half empty perspective or its usual dim view about the developers of new medical therapies, the New York Times reports that spending on prescription drugs in the US declined in 2012 by about 1 percent to $325.7 billion. The paper of record goes on to state "the first time the research firm IMS Health had recorded a decrease in United States drug sales since the company began tracking such numbers in 1957." The word "but" is the biomarker of a reporter's bias.. And so goes on to complain, "But even as the United States is in the midst of what has been called a 'golden' period in spending on drugs, some are warning that the ever-expanding use of generics has masked a growing problem for the government, insurers and others who pay the bill for prescription drugs: the rising cost of complex specialty medicines that treat cancer, rheumatoid arthritis and other diseases." The Times notes that this "potential for higher spending on drugs comes as the nation is struggling over how to contain the cost of health care, which many experts agree is a major threat to the country's fiscal condition." So the fact that there's been a drop in expenditures on medicine is twisted into a story where a potential increase in spending on drugs will bankrupt America. Except that facts get in the way. In 1960 prescription drugs were about 10 percent of health care spending. Those days people were limited to antibiotics, insulin, tranquilizers, diuretics and some crude chemotherapy drugs for cancer. In 2012 prescription drugs were about 10 percent of health care spending for diabetes, mental illness, heart disease, hypertension, targeted cancer treatments, multiple sclerosis, Parkinson's, HIV, hepatitis C and a growing array of rare diseases. Does no change in what we spend on medications as a share of health care spending sound like a threat to America's fiscal condition? And that's not taking into account the fact that each generation of new drugs not only become less expensive over time (price and generic competition ), make treating illness more affordable and, by increasing life expectancy, adds economic value. When we spend more on new therapies, we live longer, healthier lives. If the NYT mindset -- new therapies are a threat to our economic health that must be contained like a virus-- had prevailed even ten years ago we'd be spending less on medications but probably more on other types of care and living shorter, less productive lives.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog